[1]钟珊,宋筱筱,徐小红.原发性醛固酮增多症分型诊断研究进展[J].国际内分泌代谢杂志,2020,40(05):327-330.[doi:10.3760/cma.j.cn121383-20200203-02006]
 Zhong Shan,Song Xiaoxiao,Xu Xiaohong.Research progress of subtype diagnosis in primary hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2020,40(05):327-330.[doi:10.3760/cma.j.cn121383-20200203-02006]
点击复制

原发性醛固酮增多症分型诊断研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年05期
页码:
327-330
栏目:
综述
出版日期:
2020-09-20

文章信息/Info

Title:
Research progress of subtype diagnosis in primary hyperaldosteronism
作者:
钟珊宋筱筱徐小红
浙江大学医学院附属第二医院内分泌科,杭州 310009
Author(s):
Zhong Shan Song Xiaoxiao Xu Xiaohong
Department of Endocrine and Metabolic Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
关键词:
原发性醛固酮增多症 分型诊断
Keywords:
Primary hyperaldosteronism Subtype classification
DOI:
10.3760/cma.j.cn121383-20200203-02006
文献标志码:
A
摘要:
原发性醛固酮增多症是继发性高血压最常见的病因,其分型诊断的金标准是肾上腺静脉采血,但技术要求和费用消耗均较高,尚未能普及。因此,在尚不具备肾上腺静脉采血的医学中心,原发性醛固酮增多症的诊断有较大困难。近年来研究提出了多种非侵入性分型诊断方法,包括11C-MTO PET/CT、CT的拓展应用、确诊试验在分型诊断的新应用、促肾上腺皮质激素兴奋试验以及临床预测模型等,为分型诊断提供了帮助。
Abstract:
Primary hyperaldosteronism is the most common disease of secondary hypertension, the gold standard of subtype classification is adrenal vein sampling, but its technology requirement and cost are too high to popularize. In medical centers which do not equip adrenal vein sampling, diagnasis of primary hyperaldosteronism is difficult. In recent years, various non-invasive methods have been proposed, including 11C-MTO PET/CT and CT, the new application of confirmatory tests, adrenocorticotropic hormone stimulation test, and clinical risk models, all of these can play a role in subtype diagnosis.

参考文献/References:

[1] Dick SM, Queiroz M, Bernardi BL, et al. Update in diagnosis and management of primary aldosteronism[J].Clin Chem Lab Med,2018,56(3):360-372.DOI:10.1515/cclm-2018-0318.
[2] Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism:case detection, diagnosis, and treatment:an Endocrine Society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.DOI:10.1210/jc.2015-4061.
[3] Christakis I, Livesey JA, Sadler GP, et al. Laparoscopic adrenalectomy for Conn's syndrome is beneficial to patients and is cost effective in England[J].J Invest Surg,2018,31(4):300-306.DOI:10.1080/08941939.2017.1323055.
[4] Katabami T, Fukuda H, Tsukiyama H, et al. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism[J].J Hypertens,2019,37(7):1513-1520.DOI:10.1097/HJH.0000000000002070.
[5] Young WF. Primary aldosteronism:renaissance of a syndrome[J].Clin Endocrinol(Oxf),2007,66(5):607-618.DOI:10.1111/j.1365-2265.2007.02775.x.
[6] Melby JC, Spark RF, Dale SL, et al. Diagnosis and localization of aldosterone-producing adenomas by percutaneous bilateral adrenal vein catheterization[J].Prog Clin Cancer,1970,4: 175-184.
[7] Monticone S, Satoh F, Dietz AS, et al. Clinical management and outcomes of adrenal hemorrhage following adrenal vein sampling in primary aldosteronism[J].Hypertension,2016,67(1):146-152.DOI:10.1161/HYPERTENSIONAHA.115.06305.
[8] Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism[J].Surgery,2004,136(6):1227-1235.DOI:10.1016/j.surg.2004.06.051.
[9] Vonend O, Ockenfels N, Gao X, et al. Adrenal venous sampling:evaluation of the German Conn's registry[J].Hypertension,2011,57(5):990-995.DOI:10.1161/HYPERTENSIONAHA.110.168484.
[10] Mendichovszky IA, Powlson AS, Manavaki R, et al.Targeted molecular imaging in adrenal disease-an emerging role for metomidate PET-CT[J].Diagnostics(Basel),2016,6(4):42.DOI:10.3390/diagnostics6040042.
[11] Hennings J, Lindhe O, Bergstrom M, et al.
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings[J].J Clin Endocrinol Metab,2006,91(4):1410-1414.DOI:10.1210/jc.2005-2273.
[12] Burton TJ, Mackenzie IS, Balan K, et al. Evaluation of the sensitivity and specificity of(11)C-metomidate positron emission tomography(PET)-CT for lateralizing aldosterone secretion by Conn's adenomas[J].J Clin Endocrinol Metab,2012,97(1):100-109.DOI:10.1210/jc.2011-1537.
[13] O'Shea PM, O'Donoghue D, Bashari W, et al.(11)C-Metomidate PET/CT is a useful adjunct for lateralization of primary aldosteronism in routine clinical practice[J].Clin Endocrinol(Oxf),2019,90(5):670-679.DOI:10.1111/cen.13942.
[14] Bongarzone S, Basagni F, Sementa T, et al. Development of [(18)F]FAMTO:a novel fluorine-18 labelled positron emission tomography(PET)radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands[J].Nucl Med Biol,2019,68-69:14-21.DOI:10.1016/j.nucmedbio.2018.11.002.
[15] Kamemura K, Wada N, Ichijo T, et al. Significance of adrenal computed tomography in predicting laterality and indicating adrenal vein sampling in primary aldosteronism[J].J Hum Hypertens,2017,31(3):195-199.DOI:10.1038/jhh.2016.61.
[16] Umakoshi H, Tsuiki M, Takeda Y, et al. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism[J].J Clin Endocrinol Metab,2018,103(3):900-908.DOI:10.1210/jc.2017-01774.
[17] Li S, Ren Y, Zhu Y, et al. The potential clinical application of a lower bilateral adrenal limb width ratio(l/rw)in patients with bilateral primary hyperaldosteronism[J].Endocr Pract,2019,25(8):830-835.DOI:10.4158/EP-2019-0009.
[18] Li S, Sun H, Ma L, et al. Left-versus-right-adrenal-volume ratio as a screening index before adrenal venous sampling to identify unilateral primary aldosteronism patients[J].J Hypertens,2020,38(2):347-353.DOI:10.1097/HJH.0000000000002271.
[19] Umakoshi H, Ogasawara T, Takeda Y, et al. Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism[J].Clin Endocrinol(Oxf),2018,88(5):645-651.DOI:10.1111/cen.13582.
[20] Cornu E, Steichen O, Nogueira-Silva L, et al. Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism[J].Hypertension,2016,68(4):989-994.DOI:10.1161/HYPERTENSIONAHA.116.07214.
[21] Hashimura H, Shen J, Fuller PJ, et al. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism[J].Clin Endocrinol(Oxf),2018,89(3):308-313.DOI:10.1111/cen.13757.
[22] Sonoyama T, Sone M, Miyashita K, et al. Significance of adrenocorticotropin stimulation test in the diagnosis of an aldosterone-producing adenoma[J].J Clin Endocrinol Metab,2011,96(9):2771-2778.DOI:10.1210/jc.2011-0573.
[23] Jiang Y, Zhang C, Wang W, et al. Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism[J].J Clin Endocrinol Metab,2015,100(5):1837-1844.DOI:10.1210/jc.2014-3551.
[24] Moriya A, Yamamoto M, Kobayashi S, et al. ACTH stimulation test and computed tomography are useful for differentiating the subtype of primary aldosteronism[J]. Endocr J,2017,64(1):65-73.DOI:10.1507/endocrj.EJ16-0297.
[25] Kita T, Furukoji E, Sakae T, et al. Efficient screening of patients with aldosterone-producing adenoma using the ACTH stimulation test[J].Hypertens Res,2019,42(6):801-806.DOI:10.1038/s41440-018-0191-5.
[26] Kupers EM, Amar L, Raynaud A, et al. A clinical prediction score to diagnose unilateral primary aldosteronism[J].J Clin Endocrinol Metab,2012,97(10):3530-3537.DOI:10.1210/jc.2012-1917.
[27] Riester A, Fischer E, Degenhart C, et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism[J].J Clin Endocrinol Metab,2014,99(6):E1035-E1039.DOI:10.1210/jc.2013-3789.
[28] Kobayashi H, Abe M, Soma M, et al. Development and validation of subtype prediction scores for the workup of primary aldosteronism[J].J Hypertens,2018,36(11):2269-2276.DOI:10.1097/HJH.0000000000001855.
[29] Xiao L, Jiang Y, Zhang C, et al. A novel clinical nomogram to predict bilateral hyperaldosteronism in Chinese patients with primary aldosteronism[J].Clin Endocrinol(Oxf),2019,90(6):781-788.DOI:10.1111/cen.13962.

相似文献/References:

[1]高海静,温俊平.肾上腺醛固酮腺瘤术后临床转归的影响因素[J].国际内分泌代谢杂志,2016,36(01):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
 Gao Haijing,Wen Junping..Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma[J].International Journal of Endocrinology and Metabolism,2016,36(05):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
[2]郑爱琳,宋颖,罗蓉,等.关于原发性醛固酮增多症诊治的常见误区[J].国际内分泌代谢杂志,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
 Zheng Ailin,Song Ying,Luo Rong,et al.Misunderstandings in the diagnosis and treatment of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(05):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
[3]王慧萍,童安莉.原发性醛固酮增多症相关的基因突变研究进展[J].国际内分泌代谢杂志,2021,41(02):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
 Wang Huiping,Tong Anli..Research progress on gene mutation related primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(05):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
[4]郭富饶,李启富,徐智新.血浆肾素测定方法的新进展及临床意义[J].国际内分泌代谢杂志,2021,41(06):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
 Guo Furao,Li Qifu,Xu Zhixin..Advances and clinical value of plasma renin measurement[J].International Journal of Endocrinology and Metabolism,2021,41(05):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
[5]许媛 许岚 张丽华 李启富 杨淑敏.中国原发性醛固酮增多症诊断现状调查研究[J].国际内分泌代谢杂志,2022,42(04):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
 Xu Yuan,Xu Lan,Zhang Lihua,et al.Investigation on current status of diagnosis of primary aldosteronism in China[J].International Journal of Endocrinology and Metabolism,2022,42(05):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
[6]谢梦晨,郭洋洋,黄金慧,等.原发性醛固酮增多症基因型与临床表型关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
 Xie Mengchen,Guo Yangyang,Huang Jinhui,et al.Association of genotype and clinical phenotype of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2023,43(05):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
[7]王敏 杨宇宏 孙敏.原发性醛固酮增多症的组织病理学新分类及其意义[J].国际内分泌代谢杂志,2023,43(05):372.[doi:10.3760/cma.j.cn121383-20220604-06010]
 Wang Min,Yang Yuhong,Sun Min..New histopathological classification of primary aldosteronism and its significance[J].International Journal of Endocrinology and Metabolism,2023,43(05):372.[doi:10.3760/cma.j.cn121383-20220604-06010]

备注/Memo

备注/Memo:
基金项目:浙江省医药卫生科技项目(2020380946)
更新日期/Last Update: 2020-09-20